Fig. 1

CORM-3 treatment reduces infarct volume and increases the expression of NeuN and MAP2. a, c Representative TTC staining illustrates the brain infarct volume in each group at 24 h (a) and 72 h (c) after tMCAO or sham surgery; areas of infarct remain white. b, d Quantification of TTC staining in the saline- and CORM-3-treated tMCAO groups at 24 h (b) and 72 h (d) after tMCAO. Values represent corrected infarct volume as a percentage of the contralateral area (*p < 0.05, n = 6 per group). e Representative Western blot analysis of NeuN and MAP2 in the right hemisphere of each group. f, g Quantification of the Western blot analysis (*p < 0.05 vs. Sham + saline group, ^#p < 0.05 vs. tMCAO + CORM-3 group, n = 10 per group). Data are shown as mean ± SD